Physician profile
Matthew Roman
NPI 1558649061
$2,500.70
in general payments reported to CMS, 2019-2025
30 companies · $949 in 2025
The $949 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $15.43 · 2024: $1,536 · 2025: $949.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,501.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,500.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $545.13 | 2024-2025 | Breztri, Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $288.96 | 2023-2024 | Jardiance |
| Lilly USA, LLC | $200.35 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $195.10 | 2024-2025 | |
| Novo Nordisk INC | $176.02 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Exact Sciences Corporation | $100.95 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $99.89 | 2024-2025 | Veozah |
| Glaxosmithkline, LLC. | $98.71 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Amgen INC. | $80.14 | 2024-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $71.87 | 2025 | |
| Insulet Corporation | $62.76 | 2024 | Omnipod |
| Lundbeck LLC | $55.61 | 2025 | Rexulti |
| Esperion Therapeutics, INC. | $55.57 | 2024-2025 | Nexletol |
| Otsuka America Pharmaceutical, INC. | $55.03 | 2024-2025 | Rexulti |
| Hologic Sales and Service, LLC | $47.05 | 2025 | Aptima, Thinprep 2000 Processor |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $45.50 | 2025 | Zoryve |
| Cequr Corporation | $36.00 | 2024 | Cequr Simplicity |
| Merck Sharp & Dohme LLC | $34.13 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Bausch Health US, LLC | $28.50 | 2025 | Wellbutrin, Aplenzin |
| Vertos Medical, INC. | $26.83 | 2024 | Mild Device Kit |
| Gilead Sciences, INC. | $26.26 | 2025 | |
| Corcept Therapeutics | $24.60 | 2024 | Korlym |
| Xeris Pharmaceuticals, INC. | $23.36 | 2024 | Gvoke Hypopen |
| Tactile Systems Technology INC | $22.51 | 2024 | Entre Plus, Flexitouch Plus |
| Medtronic, INC. | $18.31 | 2024 | Closurefast |
| Boston Scientific Corporation | $17.09 | 2025 | X-Tack Endoscopic Helix Tacking System |
| Teva Pharmaceuticals USA, INC. | $16.87 | 2025 | Austedo Xr |
| Novartis Pharmaceuticals Corporation | $16.69 | 2024 | |
| Verona Pharma, INC. | $15.57 | 2025 | Ohtuvayre |
| Tolmar, INC. | $15.34 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Roman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.